So I've reviewed some unread emails from Auris (the exact same info is on the
Auris website as well). Remember when reading about any drug trials - approval is based on safety (will this drug hurt you) and efficacy (will this drug help you).
These are two different aspects of a drug trial, with safety arguably being the most important.
- regarding the lack of a statistically significant difference, that was related to
adverse effects only, which means that AM101 is not more likely to make you worse than if you took placebo. This is part of the safety component.
- they say that they didn't have sufficient power to demonstrate difference in efficacy over placebo, which is not surprising considering there were only 85 patients. They could only demonstrate a trend towards positive outcomes, because there just weren't enough people treated.
- regarding whether they are treating people who are out of the acute phase or not, I suspect this is for two reasons: 1) they want to have more than 85 people in their trial, so they are casting a wider net. 2) they are wanting to further prove the safety of the drug in an even broader range of people, so that more patients can be treated in both later trials, and when it comes out on the market.
- In summary, this trial did not show whether AM101 worked or not. This is not bad because they only had 85 patients - it would have to be a truly astonishing drug in order for that to happen with a multifactorial disease process like T. Basically this trial was designed to prove that AM101 is not going to burn a hole in your ear or otherwise make your symptoms worse. The phase 3 clinical trials of 600 in the EU and 330 in the US should definitively show whether AM101 works for tinnitus or not. All of this a normal part of the drug approval process. Stay tuned!
I stand by my assertion that this drug should not work outside the acute phase of tinnitus based on what I understand of the science. However I'm keeping an open mind - maybe eliminating the cochlear component (as AM101 does) makes the brain component more tolerable. I think the expansion to other groups is about increasing this number of treatable patients, which is a perfectly reasonable thing to do.
I don't really go to a lot of workshops, those are generally aimed at either clinicians or patients. However there are plenty of people around me and on TT that let me know what's in the world of T.